Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough
Massachusetts
01752
United States
Tel: 508-481-6700
Website: http://www.sunovion.com/
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
340 articles about Sunovion Pharmaceuticals Inc.
-
Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
4/26/2023
Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America
4/3/2023
Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
-
Sunovion Answers Is Named a J.D. Power 2022 Certified Customer Service Program℠
3/7/2023
Sunovion Pharmaceuticals Inc. announced that the Company’s patient support program, Sunovion Answers, has been named as a J.D. Power 2022 Certified Customer Service Program℠.
-
Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
12/1/2022
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the first patient has been enrolled in a Phase 2/3 clinical study to evaluate ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, as an adjunctive therapy in the treatment of adults living with major depressive disorder (MDD).
-
Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression
2/9/2022
Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression).
-
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
-
Sunovion Answers Is Named a J.D. Power 2021 Certified Customer Service ProgramSM
10/12/2021
Sunovion Pharmaceuticals Inc. announced that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2021 Certified Customer Service ProgramSM.
-
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
9/30/2021
Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.
-
Sunovion Presents New KYNMOBI® (apomorphine sublingual film) Study Data at the International Parkinson and Movement Disorder Society (MDS) Congress 2021
9/10/2021
Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI® (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinson’s disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.
-
Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
6/29/2021
Urovant Sciences, Inc. and Sunovion Pharmaceuticals Inc. today announced the launch of co-promotion activities for GEMTESA® (vibegron) 75 mg tablets to extend promotion to primary care physicians through the deployment of Sunovion’s multi-specialty sales.
-
Sunovion Presents Data From Marketed and Late-Stage Development Psychiatric Compounds At The American Psychiatric Association (APA) Annual Meeting 2021
5/3/2021
- An analysis compares clinical safety data of investigational agent SEP-363856 with real-world safety reports of approved antipsychotics, highlighting differentiated profile of SEP-363856 - - New post-hoc analysis indicates treatment with Latuda ® (lurasidone HCI) improved psychic and somatic anxiety in adults with bipolar depression -
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Sunovion Highlights Data from Its Late-Stage Psychiatric Medicine Pipeline at the American College of Neuropsychopharmacology (ACNP) Annual Meeting 2020
12/10/2020
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new data and analyses of late-stage compounds SEP-363856 and SEP-4199 were presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology virtual meeting, which took place December 6-9.
-
Sunovion Marks 10 Years of Addressing Serious Medical Conditions That Impact the Lives of Millions Worldwide
10/26/2020
Sunovion Pharmaceuticals Inc. announced that the company is marking ten years since it was established in October 2010.
-
Sunovion Announces the Commercial Launch of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
10/5/2020
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that KYNMOBI™ (apomorphine HCI) sublingual film is now available in the U.S. by prescription for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). KYNMO
-
Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service ProgramSM
9/22/2020
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2020 Certified Customer Service Pro
-
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.
7/16/2020
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
7/6/2020
Sunovion Pharmaceuticals Inc. (Sunovion) today announced topline results from study SEP380-201 , a global, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199, an investigational oral medicine for the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression). SEP-4199 is